Sarepta Files DMD Gene Therapy, Seeking An Accelerated Path To Market
Executive Summary
The company is seeking FDA accelerated approval of the closely watched gene therapy based on a surrogate marker and has proposed its fully enrolled Phase III trial to serve as a confirmatory study.
You may also be interested in...
Sarepta Pursues DMD Gene Therapy Accelerated Approval To Be First To Market
Sarepta has experience pursuing accelerated approvals in the US for Duchenne muscular dystrophy therapies, but with a costly gene therapy will payers require data from a controlled Phase III study?
Spotlight On High Doses Again After Pfizer Duchenne Gene Therapy Death
The death in Pfizer’s Phase I study could reflect wider safety issues for AAV-based gene therapy and could spur intervention from regulators in 2022.
Sarepta Secures $1.15bn From Roche In Ex-US DMD Gene Therapy Deal
Including upfront payments, half of development costs for SRP-9001, $1.7bn in milestone fees and royalties on sales outside the US, Sarepta pegs deal’s value at $10bn-plus.